Late-Onset Immune Checkpoint Inhibitor-Associated Myocarditis: A Systematic Review and Patient-Level Synthesis.

Priyanth Alaguraja¹, Eyad Mohammed Eldesouki², Saeed Kadri³, Atiqullah Sadaqat⁴, Ibrahim Antoun⁵

¹Department of Cardiology, Kettering General Hospital NHS Foundation Trust, Rothwell Road, Kettering NN16 8UZ, United Kingdom. Electronic address: priyanth1349@gmail.com.

²Faculty of Medicine and Surgery, Mansoura University, Mansoura,. Electronic address: eldesoukieyad@gmail.com.

³Department of Allied Health, University of Chester, Chester, United Kingdom. Electronic address: saeedkadri1997@gmail.com.

⁴Department of Curative Medicine, Faculty of Medicine, Kateb University, Kabul, Afghanistan. Electronic address: atiqullahsadaqat61@gmail.com.

⁵Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester LE3 9QP, United Kingdom. Electronic address: ia277@leicester.ac.uk.

PubMed DOI

Abstract

BACKGROUND: Immune checkpoint inhibitor (ICI)-associated myocarditis is usually considered an early toxicity, but late presentations remain poorly characterised. We aimed to describe the timing, clinical features, management and outcomes of late-onset ICI-associated myocarditis. METHODS: We conducted a PRISMA 2020 systematic review and patient-level synthesis of PubMed and Embase from inception t…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.